Gossamer Bio, Inc.
Gossamer Bio (Nasdaq: GOSS) is a clinical-stage biopharmaceutical company developing treatments for pulmonary hypertension, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its lead candidate, seralutinib, is an investigational inhaled… From the company’s description.
Over the twelve months to Jun 30, 2026, Gossamer Bio, Inc. reported revenue of $53.29M, up 32.4% from a year earlier, and a net loss of $125.22M. Its operating margin was −311.7%, and operations used $162.63M in cash. In fiscal 2025, it reported revenue of $48.47M, down 57.7% from fiscal 2024, and a net loss of $170.37M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Gossamer Bio, Inc. does
In the company’s own words
Gossamer Bio (Nasdaq: GOSS) is a clinical-stage biopharmaceutical company developing treatments for pulmonary hypertension, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its lead candidate, seralutinib, is an investigational inhaled kinase inhibitor being evaluated for PAH; the company and Chiesi jointly develop it, with Gossamer leading global development in PAH and PH-ILD and sharing U.S. commercialization activities with Chiesi. Chiesi holds exclusive commercialization rights outside the United States. Gossamer paused enrollment in its Phase 3 PH-ILD study while evaluating data and regulatory options. The company also holds an option agreement with Respira Therapeutics for RT234, an investigational inhaled, on-demand treatment candidate for PAH and PH-ILD. Gossamer’s operations center on drug research and development rather than marketed products, and its near-term focus is seralutinib. Its website is www.gossamerbio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1728117
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Gossamer Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Gossamer Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Gossamer Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Gossamer Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Gossamer Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”